Fund Companies Rights Offerings Managed Distributions Leveraged Funds IPOs Asset Classes CEF Advisors

My Fund Comparison
Initilizing list...

Tekla Healthcare Investors  as of 09/22/2017

NYSE / HQH Asset Class:  Sector Equity Funds 1 YR Lipper Avg:  10.24%

Growth of $10K

Avg Annual Total Return %
  10 YR 5 YR 1 YR YTD
Market Return 12.45% 16.12% 10.26% 26.27%
Lipper Pct. Rank 30 31 38 19
NAV Return 11.20% 15.31% 9.09% 21.80%
Lipper Pct. Rank 34 37 43 27
Premium/Discount History

Premium/Discount
10 YR Avg 5 YR Avg YTD Avg
-7.395% -1.521% -2.410%

NAV $25.97 Market Price $25.12
Net Change -$0.02 Market Change $0.07
Premium/Discount -3.27%
1 YR NAV Return 9.090%
1 YR NAV Rank 43
12-Mo Yield as of 8/31/2017 Yield Def
Income Only Yield -0.62%
Distribution Yield (Market) 7.68%
Most Recent Income Dividend $0.470
Ex-Div Date 8/25/2016
Most Recent Cap Gain Dividend $0.510
Ex-Div Date 8/24/2017
Dividend Frequency Quarterly
YTD Dividends --
YTD Capital Gains $1.460
Inception Date 4/23/1987
Fund Advisor Tekla Capital Management LLC
Manager & Tenure Team Managed
Phone 800-451-2597
Website www.teklacap.com
Total Net Assets (mil) as of -- --
% Leveraged Assets as of 9/30/2016 --
Portfolio Turnover 29.00%
Mgmt Fees 0.934%
Expense Ratio 1.100%
Fund Objective
The Fund seeks long-term capital appreciation by investing primarily in securities of companies in the health services and medical technology (health care) industries ("Health care Companies").
Top Holdings (as of 3/31/2017)
Celgene Corp ORD 7.60%
Biogen Inc ORD 7.39%
Gilead Sciences Inc ORD 6.83%
Amgen Inc ORD 5.93%
Vertex Pharmaceuticals Inc ORD 5.23%
Regeneron Pharmaceuticals Inc ORD 5.20%
Incyte Corp ORD 4.85%
Alexion Pharmaceuticals Inc ORD 4.26%
Mylan NV ORD 3.70%
Biomarin Pharmaceutical Inc ORD 3.11%
Top Sectors (as of 3/31/2017)
Health Care 88.55%
Non Classified Equity 3.28%
Consumer Services 1.66%


Resources

Aberdeen Closed-End TV

Asset TV — CEF Channel

CEF Connect

Harvest — CEFA Channel

Legg Mason CEFs

Seeking Alpha — CEFA Channel


SySys Logo

Lipper Logo
Powered by a SySys data & content management system.

© Thomson Reuters 2011. All rights reserved. Any copying, republication or redistribution of Lipper, a Thomson Reuters company, content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper, a Thomson Reuters company. Lipper, a Thomson Reuters company shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.